Forbion leads $62.5M round for neuro startup as ex-Teva R&D chief takes control; CSL Behring inks gene therapy pact in immunology
→ Forbion has led a $62.5 million round for Prilenia Therapeutics to fund two late-stage trials in Huntington’s disease and amyotrophic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
